胶囊内镜引导的主动达标治疗对比持续标准治疗在静止期克罗恩病患者中的随机对照试验
本随机对照试验纳入60例小肠受累的克罗恩病临床缓解患者,基线胶囊内镜Lewis炎症评分≥350者为高危,随机接受达标治疗优化或持续标准治疗。24个月时达标治疗组临床发作5/20(25%),标准治疗组14/20(70%),比值比0.14(95%CI 0.04-0.57;P=0.006)。结论认为胶囊内镜引导的达标治疗策略优于持续标准治疗。
要点
- 高危患者24个月临床发作率达标治疗组25% vs 标准治疗组70%,比值比0.14(95%CI 0.04-0.57;P=0.006)。
- 以Lewis炎症评分<350为 cutoff 时,达标治疗组黏膜愈合显著更常见(比值比4.5;95%CI 1.7-17.4;名义P=0.03)。
- 221次胶囊内镜检查中仅1次(0.4%)发生暂时性滞留并自行缓解。
核心结论
- 胶囊内镜引导的达标治疗策略为克罗恩病缓解期患者带来优于持续标准治疗的临床结局。
研究设计与样本
- 随机对照试验,筛查118例,纳入60例小肠受累(L1/L3)且无激素临床缓解(克罗恩病活动指数<150)的克罗恩病患者。
- 基线胶囊内镜Lewis炎症评分≥350者为高危,随机分入达标治疗优化组或持续标准治疗组;评分<350者为低危,继续标准治疗。
- 达标治疗组每6个月复查胶囊内镜以优化治疗;主要结局为24个月时高危标准治疗组对比达标治疗组的疾病恶化率(克罗恩病活动指数增加>70分且评分>150,或住院/手术)。
主要发现
- 24个月临床发作在高危达标治疗组为5/20(25%),高危标准治疗组为14/20(70%)(比值比0.14;95%CI 0.04-0.57;P=0.006)。
- 高危达标治疗组20例中治疗强化包括生物制剂剂量升级11例、启动生物制剂8例、更换生物制剂1例。
- 以Lewis炎症评分<350为 cutoff 时,达标治疗组黏膜愈合显著更常见(比值比4.5;95%CI 1.7-17.4;名义P=0.03),但以总Lewis炎症评分<450且最高段评分<350的联合标准未达显著。
- 全部持续标准治疗患者(n=40)中,复发者基线Lewis炎症评分数值上高于未复发者(分别为450,225-900 vs 225,135-600;P=0.07)。
- 221次胶囊内镜检查中发生1次(0.4%)暂时性滞留并自行缓解。
关键数值与推荐
- 高危定义为基线胶囊内镜Lewis炎症评分≥350。
- 主要结局疾病恶化定义为克罗恩病活动指数增加>70分且评分>150,或住院/手术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Optimal treat-to-target strategies for Crohn's disease (CD) are still being sought. The value of video capsule endoscopy (VCE) to guide proactive treat-to-target optimization in CD was examined. METHODS: A randomized controlled trial of patients with small bowel-involved (L1/L3) CD in corticosteroid-free clinical remission (Crohn's Disease Activity Index < 150). Patients ingested a VCE at baseline and those with a Lewis inflammatory score (LS) ≥ 350 were designated "high risk" and randomized to either treat-to-target treatment optimization or continued standard care. Treat-to-target was optimized by means of repeat VCE results every 6 months. Patients with LS < 350 ("low risk") continued standard care. The primary outcome was the rate of disease exacerbation (Crohn's Disease Activity Index increase > 70 points and score > 150 or hospitalization/surgery) in high-risk standard care vs treat-to-target groups at 24 months. RESULTS: Of 118 patients screened, 60 were enrolled. Treatment intensification in patients in the high-risk group allocated to proactive strategy comprised biologic dose escalation (n = 11 of 20), starting a biologic (n = 8 of 20), or swapping biologics (n = 1 of 20). The primary outcome, clinical flare by 24 months, occurred in 5 of 20 (25%) of high-risk treat-to-target patients vs 14 of 20 (70%) of the high-risk standard-care group (odds ratio, 0.14; 95% CI, 0.04-0.57; P = .006). Mucosal healing was significantly more common among the treat-to-target group when determined by a cutoff LS < 350 (odds ratio, 4.5; 95% CI, 1.7-17.4; nominal P value = .03), but not by the combined scores of total LS < 450 and highest-segment LS < 350. Among all patients continuing standard care (n = 40), baseline LS was numerically higher among relapsers vs nonrelapsers (450, 225-900 vs 225, 135-600, respectively; P = .07). Of 221 VCEs ingested, there was a single (0.4%) temporarily retained spontaneously resolved event. CONCLUSIONS: A VCE-guided treat-to-target strategy for patients with CD in remission confers superior clinical outcomes compared with continued standard care. CLINICALTRIALS: gov, Number: NCT03555058.
引用
- Ben-Horin S, Lahat A, Ungar B, et al. Capsule Endoscopy-Guided Proactive Treat-to-Target Versus Continued Standard Care in Patients With Quiescent Crohn's Disease: A Randomized Controlled Trial. Gastroenterology. 2025. PMID: 40107519. doi:10.1053/j.gastro.2025.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。